AES

About AES

Accelerated Enrollment Solutions (AES) operates as a business unit of the global contract research organization (CRO) PPD, which is now a part of Thermo Fisher Scientific. Established in 2018, AES was formed to provide pharmaceutical and biotechnology companies with specialized site and patient enrollment solutions for clinical trials. The company's creation integrated the capabilities of several industry leaders, including Synexus, a global network of research sites; Acurian, a patient enrollment and retention specialist; and Optimal Research, which focuses on vaccines and oncology trials.

The core business of AES is to accelerate clinical trial timelines and provide budget certainty by optimizing patient recruitment and site management. The company serves sponsors and CROs by offering a model that can deliver a significant portion, or even all, of the required patient enrollment for a study from a unified network. This is achieved by identifying qualified patient populations first, using predictive enrollment models, and then activating sites accordingly, which reduces the number of underperforming or non-enrolling sites. This approach addresses major industry challenges, such as slow patient recruitment and investigator site capacity limitations.

AES's service portfolio is comprehensive, combining a vast network of over 180 dedicated research sites across five continents with advanced patient identification and engagement capabilities. Through strategic acquisitions, such as the global site business from Bioclinica in 2019, AES expanded its geographic footprint into key markets including China, Latin America, and Western Europe, complementing its existing presence in North America, Europe, and South Africa. The company offers differentiated services for a variety of indications and has developed specific solutions like the PatientAdvantage program, which integrates multiple services for a patient-centric approach, and a just-in-time model for oncology trials.